Tau hypothesis gets fillip in wake of Aduhelm approval

25 June 2021
vials_biotech_lab_drugs_big

Protein specialist Prothena (Nasdaq: PRTA) is to receive $80 million from Bristol Myers Squibb (NYSE: BMY) after the New York-based firm opted in on a program in Alzheimer’s.

The money brings to $230 million the total BMS has paid under the collaboration, with up to around $2 billion more on the line for rights, milestone payments and royalties, in the best case scenario.

The global dementia research community has been given a shot in the arm by the recent approval of Biogen’s (Nasdaq: BIIB) Aduhelm (aducanumab), the first new Alzheimer’s therapy in decades.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology